Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Role of the Interaction Between AGEs and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02818465

Acronym

RAGE-VASCU

Enrollment

100

Registered

2016-06-29

Start date

2015-03-30

Completion date

2017-11-16

Last updated

2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialyzed Patients

Brief summary

Chronic kidney disease (CKD) is associated with an extensive vasculopathy and high cardiovascular mortality as well as an accumulation of uremic toxins. Among the latest, advanced glycation end-products (AGEs) interact with RAGE. Investigators aimed to analyze the role of RAGE in the calcification process of hemodialyzed patients, in a correlative and prospective study. Vascular calcifications will be assessed by Xray and tomodentimetry while accumulation of AGEs will be measured in the serum and in the skin (non invasive). Additionally factors influencing RAGE activation such as genetic polymorphism and level of soluble forms of RAGE will be measured and analyzed.

Interventions

OTHERVascular calcifications by Xray

OTHERVascular calcifications by tomodentimetry

BIOLOGICALBlood sample withdrawn

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Renal impairment * Hemodialysis for more than 3 months * Have agreed to participate in research * Affiliated to a social security scheme * major

Exclusion criteria

* Diabetes , for diabetes induces accelerated formation of advanced glycation end products , which could then be a confounding factor in our study. * Protected by law . * minors * pregnant women * Matt or pigmented skin because the skin hyperpigmentation interfere with reading the skin fluorescence giving falsely elevated values . * Having an aneurysm of the abdominal aorta known * Suffering from a progressive neoplastic disease

Design outcomes

Primary

Measure	Time frame
Frammingham Score	up to 12 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026